Triad Wealth Partners’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Triad Wealth Partners's NVS Position: Q3 2026 in Review
Triad Wealth Partners increased its Novartis (NVS) stake by 1.5% in Q3 2026, buying an estimated $4.4K and bringing the position to 1,978 shares worth $282K. The position accounts for 0.02% of the portfolio, ranked #446.
Triad Wealth Partners first reported a position in NVS in Q2 2024 and has held it in 4 quarters since. The position peaked at $300K in Q2 2026. 1,561 funds tracked by Wall St. Rank hold NVS as of Q3 2026.
- Triad Wealth Partners held 1,978 shares of Novartis worth $282K as of Q3 2026.
- Triad Wealth Partners bought 29 Novartis shares in Q3 2026, an estimated $4.4K.
- Novartis made up 0.02% of Triad Wealth Partners's portfolio in Q3 2026, its #446 holding.
- Triad Wealth Partners first reported a position in Novartis in Q2 2024 and has held it in 4 quarters since.
- Triad Wealth Partners's Novartis position peaked at $300K in Q2 2026.
- 1,561 funds tracked by Wall St. Rank held Novartis as of Q3 2026.
Based on Triad Wealth Partners's 13F filing for Q3 2026, filed 26 Oct 2026.